This is unpublished

Jesse
Levin

MD

Faculty

Hospitalist

Pinned

Academic

Clinical Associate Professor, Medicine

Education & Training

MD, New York Medical College, Valhalla, NY (2009)
Internal Medicine Internship and Residency, UCLA Medical Center, Los Angeles, CA (2009–2012)

Ho V, Kim HT, Li S, Hochberg E, Cutler C, Lee SJ, Fisher DC, Milford E, Kao G, Daley H, Levin J, Ng A, Mauch P, Alyea EP, Antin JH, Soiffer, RJ. Partial CD8+ T Cell Depletion of Allogeneic Peripheral Blood Stem Cell Transplantation is Insufficient to Prevent GVHD. 2004 Dec; Bone Marrow Transplantation 34(11): 987–994.
Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. 2004 May; Biology of Blood and Marrow Transplantation 10(5): 328–336.
Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH. Safety and Efficacy of Denileukin Diftitox in Patients with Steroid Refractory Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. 2004 15 Aug; Blood 104(4): 1224–1226.
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E. Rituximab for steroid-refractory chronic graft-versus-host disease. 2006 Jul 15; Blood 108(2): 756–762.